巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Connect Biopharma Holdings Limited

    CNTB
    1.240
    0.010
    0.81%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Connect Biopharma Holdings Limited - 延遲價格・最後更新於 29/09 12:00
    最高位
    1.270
    最低位
    1.190
    開市價
    --
    前收市價
    1.230
    成交量(千)
    0.20
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    68.22
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    24.700 - 0.557
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Connect Biopharma Holdings Limited
    證券代碼
    CNTB.US
    所屬板塊
    Biotechnology
    公司業務
    Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.
    發行量
    55076319
    公司總部
    6 Beijing West Road, East R&D Building, 3rd Floor, Science and Technology Park, Jiangsu Province
    公司網址
    https://www.connectbiopharm.com
    公司電話
    +86 51253577866

    納斯達克生物科技指數跌超2%

    格隆匯·
    納斯達克生物科技指數跌超2%

    納斯達克生物科技指數跌超2%

    格隆匯·
    納斯達克生物科技指數跌超2%

    關於

    Connect Biopharma Holdings Limited(CNTB.US)所屬的行業板塊為Biotechnology。
    Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.
    詳細公司背景可參考: https://www.connectbiopharm.com